David Hung - 04 Jun 2025 Form 4 Insider Report for NovoCure Ltd (NVCR)

Reporting relationship: Director
Issuer ticker: NVCR
Reported as of: 04 Jun 2025
Net transaction value: $0
SEC form: 4
Accepted by SEC: 06 Jun 2025, 16:14:44 UTC
Prior SEC filing: 04 Jun 2025
Next SEC filing: 18 Jun 2025
Source filing: View source filing
Reporting owner signature: Steven Robbins, as attorney in fact for Hung, David

Key filing fact

David Hung filed Form 4 for NovoCure Ltd (NVCR) on 06 Jun 2025.

Key facts

This page summarizes David Hung's Form 4 filing for NovoCure Ltd (NVCR).
2 reported transactions and 1 derivative row are listed below.
Accepted by SEC: 06 Jun 2025, 16:14.

Change

Previous filing in this sequence was filed on 04 Jun 2025.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001310880 Primary reporting owner

Hung David

Relationship: Director
Address: C/O NOVOCURE INC., 1550 LIBERTY RIDGE DRIVE, SUITE 115, WAYNE
Signature: Steven Robbins, as attorney in fact for Hung, David
Signature date: 06 Jun 2025

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

NVCR transaction

Ordinary Shares

Award

Transaction value: $0
Shares: +11,215
Change %: +92%
Price: $0.000000
Shares after: 23,410
Date: 04 Jun 2025
Ownership: Direct
Footnotes: F1

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

NVCR transaction Derivative

Stock Option (Right to Buy)

Award

Transaction value: $0
Shares: +16,697
Change %
Price: $0.000000
Shares after: 16,697
Date: 04 Jun 2025
Ownership: Direct
Underlying class: Ordinary Shares
Underlying amount: 16,697
Exercise price: $16.72
Footnotes: F2

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 2 footnotes

Footnote F1

Represents restricted stock units that are scheduled to vest 100% on the earlier of the following dates: (i) the first anniversary of the grant date or (ii) the day immediately preceding the Company's 2026 annual general meeting of shareholders.

Footnote F2

Options to buy ordinary shares will fully vest and become exercisable on the earlier of the following dates: (i) the first anniversary of the grant date or (ii) the day immediately preceding the Company's 2026 annual general meeting of shareholders.